Cipher Pharmaceuticals (TSE:CPH) has released an update.
Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Cipher Pharmaceuticals announced that their partner, Moberg Pharma, reported disappointing results from a Phase 3 study of MOB-015, a nail fungus treatment, which did not meet its primary endpoint. Despite this setback, Cipher remains focused on its recent acquisition of the Natroba business and sees significant growth potential in the U.S. and international markets.
For further insights into TSE:CPH stock, check out TipRanks’ Stock Analysis page.
